Wall Street brokerages forecast that Intellia Therapeutics Inc (NASDAQ:NTLA) will announce earnings per share (EPS) of ($0.52) for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Intellia Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.64) and the highest estimate coming in at ($0.34). Intellia Therapeutics reported earnings of ($0.61) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 14.8%. The business is scheduled to report its next quarterly earnings results on Wednesday, March 13th.
On average, analysts expect that Intellia Therapeutics will report full-year earnings of ($2.05) per share for the current fiscal year, with EPS estimates ranging from ($2.20) to ($1.89). For the next fiscal year, analysts anticipate that the business will post earnings of ($2.56) per share, with EPS estimates ranging from ($3.35) to ($1.18). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that that provide coverage for Intellia Therapeutics.
Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Wednesday, October 31st. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.05). Intellia Therapeutics had a negative return on equity of 31.70% and a negative net margin of 308.81%. The business had revenue of $7.41 million for the quarter, compared to analyst estimates of $11.58 million. During the same period last year, the firm posted ($0.44) EPS. Intellia Therapeutics’s quarterly revenue was up 1.2% on a year-over-year basis.
Intellia Therapeutics stock opened at $19.34 on Tuesday. Intellia Therapeutics has a 52 week low of $16.33 and a 52 week high of $35.99. The firm has a market cap of $801.09 million, a PE ratio of -10.29 and a beta of 3.87.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Macquarie Group Ltd. acquired a new stake in shares of Intellia Therapeutics in the second quarter valued at about $101,000. Patriot Financial Group Insurance Agency LLC acquired a new stake in shares of Intellia Therapeutics in the third quarter valued at about $116,000. Nikko Asset Management Americas Inc. acquired a new stake in shares of Intellia Therapeutics in the third quarter valued at about $141,000. Legal & General Group Plc increased its stake in shares of Intellia Therapeutics by 75.4% in the second quarter. Legal & General Group Plc now owns 5,427 shares of the company’s stock valued at $149,000 after buying an additional 2,333 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Intellia Therapeutics by 519.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,733 shares of the company’s stock valued at $157,000 after buying an additional 4,807 shares during the period. 66.59% of the stock is owned by institutional investors and hedge funds.
About Intellia Therapeutics
Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.
Featured Story: Stock Symbols and CUSIP Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.